r Angiotensin II (AngII) is crucial in cardiovascular regulation in perinatal mammalians. r Here we show that AngII increases twitch Ca 2+ transients of mouse immature but not mature cardiomyocytes by robustly activating Ca V 1.2 L-type Ca 2+ channels through a novel signalling pathway involving angiotensin type 1 (AT 1 ) receptors, β-arrestin2 and casein kinase 2.
Introduction
The renin-angiotensin system (RAS) is an important regulator of the cardiovascular system and controls sodium balance, body fluid volumes and arterial pressure (Hall, 2003; Paul et al. 2006; Karnik et al. 2015) . Classically, RAS was viewed as an endocrinological system (Hall, 2003) . The enzyme renin secreted from juxtaglomerular cells in the kidney digests angiotensinogen produced by the liver to a decapeptide, angiotensin I, in the plasma. Angiotensin I is then converted to an octapeptide, angiotensin II (AngII), by the angiotensin-converting enzyme in the pulmonary circulation. AngII is a major player in this system and activates two specific G-protein-coupled receptors, angiotensin type 1 (AT 1 ) and angiotensin type 2 (AT 2 ) receptors (Hunyady & Catt, 2006; Karnik et al. 2015) . AT 1 receptors mediate most of the known effects of AngII, whereas the functional role of AT 2 receptors is still under extensive investigation. AT 1 receptors activate various heterotrimeric G proteins (G q/11 , G 12/13 and G i ) and β-arrestins. Although β-arrestins were originally discovered to desensitize activated G-protein-coupled receptors, it is now well established that β-arrestins mediate G-protein-independent signals on their own right (Shukla et al. 2011) . In addition to the plasma RAS, many tissues, including the heart, possess many components of RAS and produce AngII in situ to regulate their own functions (local RAS) (Paul et al. 2006; Bader, 2010) . RAS also plays significant roles in cardiovascular diseases such as hypertension, atherosclerosis, and cardiac hypertrophy and failure as evidenced by the fact that inhibitors of the angiotensin-converting enzyme and AT 1 receptors significantly improve the outcome of these diseases (Jong et al. 2003; Pfeffer et al. 2003) .
In fetal and postnatal development, the plasma and local RAS are extremely important (Heymann et al. 1981; Paul et al. 2006) . In general, all components of RAS begin to be expressed early in fetal development, and their amounts culminate at the perinatal period. Indeed, the plasma renin concentration and activity are higher in newborns than adults in various animals, including humans (Wallace et al. 1980; Varga et al. 1981) . At the time of birth, neonates experience major haemodynamic changes such as rapid increase in pulmonary blood flow, removal of placental circulation, closure of several sites of shunting within the heart and great vessels, and changes in cardiac output and its distribution (Hooper et al. 2015) . Left ventricular output increases as much as ß3 times at birth, and the systemic blood pressure increases immediately after birth and continues to rise for several weeks, concomitant with an increase in systemic vascular resistance. RAS together with the sympathetic nervous system is thought to play a critical role in these changes (Heymann et al. 1981) . Furthermore, infants born vaginally have higher circulating concentrations of AngII than those delivered by caesarean section (Lumbers & Reid, 1977) , and a minor degree of haemorrhage results in a marked increase in plasma AngII concentration (Broughton Pipkin et al. 1974) , indicating that RAS is critical for newborns' response to haemodynamic insults. Indeed, mice deficient of angiotensinogen or AT 1 receptors exhibit ß50% perinatal lethargy (Kim et al. 1995; Oliverio et al. 1998) .
Although it is well established that AngII causes vascular contraction, little is known about the effect of AngII on contraction of the immature heart. Herein, we have highlighted that AngII markedly increases twitch Ca 2+ transients of immature but not mature cardiomyocytes by robustly increasing L-type Ca V 1.2 Ca 2+ (Ca V 1.2) channel currents through a novel pathway composed of AT 1 receptors, β-arrestin2 and casein kinase 2 (CK2). Thus, β-arrestin-biased AT 1 receptor agonists, which have not only a positive inotropic effect but also an anti-apoptotic effect on cardiomyocytes, may be used as valuable therapeutics for paediatric heart failure in the future (Kim et al. 2012) .
Methods

Ethical approval
All animals used in this study received humane care in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. All experimental procedures were carried out in accordance with the Guidelines for Animal Experimentation of Shinshu University and approved by the Committee for Animal Experimentation (Approval numbers 250062 and 280035). All mice were given free access to water and standard diet throughout the study, and maintained in a temperature-(21-26°C) and humidity-(50-60%) controlled room with a 12 h light/dark cycle. All experimental mice were deeply anaesthetized with 0.3 mg kg -1 medetomidine (Domitor, Nippon Zenyaku Kogyo Co., Fukushima, Japan), 4.0 mg kg -1 midazolam (Midazolam Sandoz, Novartis, Tokyo, Japan) and 5.0 mg kg -1 butorphanol (Vetorphale, Meiji Seika Pharma Co., Tokyo, Japan), I.P., or isoflurane (Escain, Mylan Seiyaku, Osaka, Japan) inhalation (mouse pups). We conform to the principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology (Grundy, 2015) . All C57BL/6 mice were purchased from Japan SLC Inc.
Isolation of cardiomyocytes
Cardiomyocytes from male C57BL/6 mice at postnatal days (P) 10, P28-34 and P56-62 were enzymatically isolated as previously described (Horiuchi-Hirose et al. 2011) . Briefly, the hearts were removed from anaesthetized mice, mounted on the Langendorff apparatus with modified Tyrode solution containing (mM) 136.5 NaCl (Wako Pure Chemical Industries, Osaka, Japan), 5.4 KCl (Wako), 1.8 CaCl 2 (Wako), 0.53 MgCl 2 (Wako), 5.5 Hepes (Dojindo, Kumamoto, Japan) and 5.5 glucose (Wako) (pH 7.4 with NaOH), and digested with Ca 2+ -free Tyrode solution containing 0.80 mg ml -1 collagenase (Nitta Gelatin Inc., Osaka, Japan), 0.06 mg ml -1 protease (Sigma-Aldrich, Tokyo, Japan), 1.20 mg ml -1 hyaluronidase (Sigma-Aldrich), 0.03 mg ml -1 DNase I (Roche, Tokyo, Japan) and 0.50 mg ml -1 BSA (Wako) at 37°C for 2 min. Isolated cardiomyocytes were suspended in Ca 2+ -free Tyrode solution containing 1 mg ml -1 BSA at room temperature, and the Ca 2+ concentration was gradually increased to 1.8 mM. After that, cardiomyocytes were treated with vehicle (deionized water) or AngII (Sigma-Aldrich).
Cell cultures and preparations
Anaesthetized neonatal (P0 or P1) C57BL/6 mice were decapitated and hearts were then removed aseptically. Primary cultures of cardiomyocytes were prepared from the hearts by using the Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corp., Lakewood, NJ, USA). To enrich cardiomyocytes, the collected cells were plated onto plastic culture dishes in low-glucose Dulbecco's modified Eagle's medium (DMEM) plus GlutaMAX (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum, 100 units ml -1 penicillin (Thermo Fisher Scientific) and 100 μg ml -1 streptomycin (Thermo Fisher Scientific) at 37°C and 5% CO 2 for 60 min and then plated onto gelatin-(Difco, Becton, Dickinson Company, Franklin Lakes, NJ) and fibronectin-(Sigma-Aldrich) coated glass bottom dishes or coverslips. After culture in serum-free medium for 24 h, the cardiomyocytes were treated with vehicle (deionized water) or AngII. We confirmed that these cardiomyocytes soon after isolation and those cultured for a few days exhibited almost the same degree of response of L-type Ca 2+ channels to AngII.
HL-1 cardiomyocytes were kindly provided by Dr William C. Claycomb (Louisiana State University Health Science Centre, New Orleans, LA, USA) and were cultured in Claycomb Medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 units ml -1 penicillin, 100 μg ml
streptomycin, 2 mM L-glutamine (Sigma-Aldrich) and 100 μM noradrenaline (Sigma-Aldrich) at 37°C and 5% CO 2 on gelatin/fibronectin-coated flasks (Claycomb et al. 1998) . HL-1 cardiomyocytes spontaneously beating were passaged when they reached 100% confluency. For electrophysiological experiments, HL-1 cardiomyocytes were plated onto gelatin/fibronectin-coated coverslips at low density. After culture in noradrenaline-and serum-free Claycomb medium for 24 h, HL-1 cardiomyocytes were treated with vehicle (deionized water) or AngII. For introduction of small hairpin (sh) RNAs with red fluorescent protein (RFP) or cDNA of C-terminal Src kinase (CSK) with green fluorescent protein (GFP) in HL-1 cardiomyocytes, lentiviral stocks were produced in HEK293T cells (American Type Culture Collection, Manassas, VA, USA) by cotransfection of the packaging plasmids pMD.G (VSVG envelope), pMDLg/pRRE (gag-pol plasmid) and pRSV-Rev (rev plasmid) with corresponding lentiviral constructs using polyethylenimine (Polysciences, Inc., Warrington, PA, USA) and concentrated by polybrene (Sigma-Aldrich) (Kojima et al. 2014) . Whole-cell patch-clamp recordings were performed with RFP-or GFP-positive cells.
TsA201 human embryonic kidney cells (European Collection of Authenticated Cell, Salisbury, UK) were cultured in low-glucose DMEM plus GlutaMAX, 10% fetal bovine serum, 100 units ml -1 penicillin and 100 μg ml -1 streptomycin at 37°C and 5% CO 2 . TsA201 cells were grown to ß70% confluency in plastic dishes and transiently transfected with an equimolar ratio of cDNA encoding Ca V 1.2 α 1c , β 2c and α 2 δ 1 subunits (1.0, 0.7, and 0.8 μg of plasmid DNA per 35 mm dish, respectively) and other proteins by the calcium phosphate method. For electrophysiological experiments, a 10-fold lower ratio of cDNA encoding enhanced GFP (EGFP) was added to each transfection mixture as an indicator of successful transfection, and 30 h after transfection, cells were plated onto collagen-(Nitta gelatin) coated coverslips at low density. Experiments were performed with 48-56 h post-transfection cells.
Plasmid construction
The cDNA encoding rabbit α 1C was generously given by Dr William A. Catterall (University of Washington, Seattle, WA, USA). Ca V 1.2α 1C 1821 [Ca V 1.2α 1c subunit devoid of its distal C-terminus 1822-2171 (DCT)] was generated by PCR using antisense primers containing a stop codon and SalI restriction site. All primer J Physiol 595.13 sequences used in this study are listed in Table 1 . The PCR products were subcloned into a blunt-ended pBlueScript SK-vector and again subcloned into the EcoRV/SalI site of the Ca V 1.2α 1C subunit. For immunoblotting and immunoprecipitation assays, hemagglutinin (HA)-tagged Ca V 1.2α 1C and HA-Ca V 1.2α 1C 1821 were used. An HA-epitope was inserted into the extracellular loop between S5 and S6 in domain II as previously described (Nakada et al. 2012) . To generate HA-Ca V 1.2α 1C DCT and 3xFLAG-tagged Ca V 1.2α 1C DCT, the cDNA encoding amino acids 1822-2171 of Ca V 1.2α 1C was amplified by PCR and then subcloned into pCMV-HA (Clontech Laboratories, Inc., Mountain View, CA, USA) or p3xFLAG-CMV-10 (Sigma-Aldrich).
The cDNAs of Ca V β 2 c and Ca V α 2 δ 1 subunits were isolated with RT-PCR from a rat heart cDNA library. The cDNAs of CK2α, CK2α' , CK2β, p27
Kip1 (p27), c-Src and CSK were isolated with RT-PCR from a mouse heart cDNA library. These cDNAs were subcloned into pcDNA3.1, pCMV-HA, pCMV-Myc (Clontech) or p3xFLAG-CMV-10. Single amino acid substitution mutants [Ca V 1.2α 1C 1821T1704A (Thr 1704 of α 1C was substituted with alanine), Myc-p27Y88F (Tyr 88 of p27 was substituted with phenylalanine, Y88F), and Myc-p27Y88E (Tyr 88 of p27 was substituted with glutamic acid)] were generated with the QuickChange Site-Directed Mutagenesis Kit (Stratagene, Agilent Technologies, Tokyo, Japan) according to the manufacturer's instructions.
The cDNAs of CSK were isolated with RT-PCR from a mouse heart cDNA library and then subcloned into lentiviral transfer plasmid CSII-EF-MCS-IRES-hrGFP [kindly provided by Dr Hiroyuki Miyoshi (RIKEN BRC, Tsukuba, Japan)]. To prepare the shRNA expression vectors for p27, G q , G 11 , β-arrestin1, β-arrestin2, CK2α, CK2α' and CK2β, the double stranded DNA oligo encoding a sense-loop-antisense sequence to the targeted genes was inserted into lentiviral shRNA expression vector pRSI9-U6-(sh)-UbiC-TagRFP-2A-Puro (Addgene, Cambridge, MA, USA). All DNA oligo sequences used in this study are listed in Table 1 .
Antibodies
Antibodies against the following proteins were used: Ca V 1.2α 1c (1:2000, ACC-003, Alomone Labs, Jerusalem, Israel), α-tubulin (1:3000, T5168, Sigma-Aldrich), G q/11 (1:500, sc-392, Santa Cruz Biotechnology, Dallas, TX, USA), β-arrestin1 (1:1000, 610550, BD Transduction Laboratories, Franklin Lakes, NJ, USA), β-arrestin2 (1:2000, ab167047, Abcam, Cambridge, UK), CSK (1:1000, H00001445-M01, Abnova, Taipei, Taiwan), CK2β (1:1000, MAB0817, Abnova), HA (1:10 000, M180-3, MBL, Nagoya, Japan), Myc (1:10 000, M192-3, MBL), control mouse IgG2b (M077-3, MBL), FLAG (1:5000, F1804, Sigma-Aldrich), p27 (1:5000, 610241, BD Trans- 
Ca
2+ imaging
The imaging of twitch Ca 2+ transients was performed as previously described (Nakada et al. 2012) . Briefly, cardiomyocytes in glass bottom dishes were incubated with 6 μM Fluo 4/AM (Dojindo) plus 0.01% Cremophore EL (Sigma-Aldrich) and 0.02% BSA in serum-free DMEM for 45 min at 37°C and 5% CO 2 followed by de-esterification. Cardiomyocytes were superfused with modified Tyrode solution at room temperature and paced with 1 ms pulses of 50 V at 0.3 Hz across the 20 mm incubation chamber. Fluorescence images were acquired with an LSM 7 LIVE laser-scanning microscope with a 20×/0.8 plan apochromatic objective (Carl Zeiss, Jena, Germany). Each image was taken with 128 pixels × 128 pixels every 2.8 ms. The time course of Ca 2+ transients was assessed from the fluorescence change in individual cardiomyocytes selected by the ROI tool. An increment in fluorescence intensity from baseline was measured and normalized to baseline intensity ( F/F 0 ).
Electrophysiology
Ionic and gating currents of Ca V 1.2 channels were recorded in the whole-cell configuration of the patch-clamp technique at 35-36°C with a patch-clamp amplifier (Axopatch 200B, Molecular Devices, Sunnyvale, CA) and sampled at 10 kHz after low-pass filtering at 5 kHz (Horiuchi-Hirose et al. 2011) . Patch pipettes (2-3 M ) were fabricated from borosilicate glass capillaries (Kimax-51, Kimble Glass, Vineland, NJ, USA) and coated with Sylgard 184 (Dow Corning Toray Co., Tokyo, Japan). Series resistance was always kept less than 7 M and routinely compensated for with the amplifier by ß75%. 
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AS GCCGGCTGGGGCTCAGTTCAA * 1 PCR products were subcloned into the expression vectors after digestion with the restriction enzymes indicated. * 2 Primers used for the quickchange site-directed mutagenesis system. * 3 PCR products were subcloned into the expression vectors by an in-fusion cloning system. * 4 Sense and antisense oligonucleotides were annealed and subcloned into the shRNA lentivector linearized with BbsI.
between -40 and +70 mV with a 10 mV increment every 5 s. Coupling efficiency for recombinant Ca V 1.2 channels in tsA201 cells was assessed with the intracellular solution containing (mM): 135 CsCl, 10 EGTA, 1 MgCl 2 , 4 MgATP (pH 7.3 with CsOH). The extracellular bath solution contained (mM): 150 Tris (Wako), 10 BaCl 2 , 1 MgCl 2 and 10 glucose (pH 7.4 with HCl) (Hulme et al. 2006 ). Gating charge movement was measured by applying a series of test pulses from the holding potential of -80 mV to potentials between +60 mV and +80 mV with a 2 mV increment every 5 s and integrating the ON gating charge for 2 ms from the beginning at the reversal potential of Ca V 1.2 channels. Ba 2+ tail currents were recorded after repolarization to -50 mV from each test pulse.
Immunoblotting and immunoprecipitation
Cells were lysed with ice-cold lysis buffer composed of 10 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA (Dojindo), 1% Triton-X (Sigma-Aldrich) and 10% glycerol (Wako) containing a protease inhibitor cocktail (Nacalai tesque, Kyoto, Japan). For analysis of Tyr 88 phosphorylation of p27, the lysis buffer with the phosphatase inhibitor cocktail (Nacalai tesque) and without EDTA was used. After sonication for 5 s and gentle rocking at 4°C for 30 min, lysates were centrifuged at 10 000 g at 4°C for 30 min in order to remove insoluble materials. In experiments shown in Fig. 7C , lysates were ultracentrifuged at 100 000 g at 4°C for 1 h to further remove insoluble materials. The protein concentrations of samples were measured by a BCA protein assay kit (Thermo Fisher Scientific). For immunoprecipitation, lysates (250 μg) were incubated with antibodies (2 μg) covalently linked to Protein A-Sepharose or Protein G-Sepharose (17-6002-35, GE Healthcare Japan, Tokyo, Japan) at 4°C for 2 h, and the immunoprecipitates were then extensively washed with lysis buffer.
For immunoblotting, samples (10-50 μg per lane) were separated on 7.5% or 10% SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes. Non-specific binding was blocked with Blocking One (Nacalai tesque) or Blocking One-P (Nacalai tesque) for 30 min at room temperature. Membranes were incubated with primary antibodies overnight at 4°C. After being washed with TBST, membranes were reacted with HRP-conjugated secondary antibodies for 1 h at room temperature. The bound secondary antibody was visualized with Immobilon Western (Sigma-Aldrich) according to the manufacturer's instructions. Signal intensities of bands were quantified with the Gel analysis program of the ImageJ software (NIH, Bethesda, MD, USA).
Statistics
All data are expressed as means ± SEM. Statistical significance was evaluated using the unpaired Student's t test. For multiple comparisons of data, ANOVA followed by Dunnett's test was used unless otherwise indicated. P < 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS version 23 software (SPSS Inc., Armonk, NY, USA).
Results
AngII increases twitch Ca 2+ transients in neonatal but not adult ventricular cardiomyocytes
It is of debate whether AngII augments cardiac contractility (Allen et al. 1988; Ikenouchi et al. 1994; Petroff et al. 2000; Aiello & Cingolani, 2001; Bkaily et al. 2005; Gassanov et al. 2006) . We hypothesized that this is partly because AngII differentially regulates cardiac contractility at distinct developmental stages. Thus, we first compared the effects of AngII on twitch Ca 2+ transients in mouse neonatal and adult ventricular cardiomyocytes (NVCMs and AVCMs, respectively). In NVCMs, 2 h treatment of AngII (3 μM) significantly increased the peak of Ca 2+ transients (Fig. 1A) . However, AngII had no significant effect on Ca 2+ transients in AVCMs (Fig. 1A) . These results suggested that AngII may exert a positive inotropic effect in immature cardiomyocytes. (Fig. 1B) , an atrial myocyte cell line, HL-1 (Fig. 1D) , and mouse neonatal atrial cardiomyocytes (Fig. 1D ). This response to AngII, however, gradually decreased in an age-dependent manner and was eventually abolished in adult ventricular and atrial cardiomyocytes (P56-62) (Fig. 1B-D) . AngII increased the amplitude of peak L-type Ca 2+ channel currents in HL-1 cardiomyocytes in a concentration-dependent manner with EC 50 and Hill coefficient of 360 nM and 0.90, respectively (Fig. 1E) .
Mechanism employed by AngII to increase L-type Ca 2+ channel activity
To clarify the mechanisms by which AngII augments L-type Ca 2+ channel currents, we measured, in NVCMs, the gating charge upon depolarization to the reversal potential of L-type Ca 2+ channels (E rev ) and the amplitude of peak tail currents after repolarization from E rev to -50 mV ( Fig. 2A) . AngII did not increase gating charges but increased the amplitude of tail currents in a time-dependent manner within 2 h (Fig. 2B and C) . As a result, AngII increased the ratio of the amplitude of tail currents to gating charges (Fig. 2D) We henceforth analysed the signal transduction system mediating the effect of AngII on L-type Ca 2+ channels in immature cardiomyocytes. We found that a selective AT 1 receptor antagonist, candesartan (10 μM, AdooQ BioScience, Irvine, CA, USA), but not a selective AT 2 receptor antagonist, PD123319 (3 μM, Wako), completely abolished the AngII-induced increase in peak L-type Ca 2+ channel current densities in HL-1 cardiomyocytes (Fig. 3A) , indicating the involvement of AT 1 receptors in this response. Furthermore, knockdown of β-arrestin2 but not G q/11 or β-arrestin1 significantly suppressed the effect of AngII (Fig. 3B) . Consistent with this, a β-arrestin-biased AT 1 receptor agonist, TRV027 (customarily produced by Peptide Institute, Inc., Osaka, Japan), activated L-type Ca 2+ channels as efficaciously as AngII in NVCMs (Fig. 3C) . These results indicated that AngII activates L-type Ca 2+ channels through AT 1 receptors and β-arrestin2 in immature cardiomyocytes.
SFKs and CK2α'β are required for the effect of AngII on L-type Ca 2+ channels
The results described in Fig. 2 indicated that AngII post-translationally modifies L-type Ca 2+ channels in immature cardiomyocytes. Thus, to elucidate possible involvement of protein kinases in the AngII-induced response (Hunyady & Catt, 2006; Karnik et al. 2015) , we examined, in NVCMs, the effects of an array of pharmacological inhibitors of kinases that are known to be activated by AngII and/or to regulate L-type Ca 2+ channels (Fig. 4A ). The effect of AngII was not affected by pretreatment of an epidermal growth factor receptor inhibitor, erlotinib (0.1 μM, Cayman Chemical Company, Ann Arbor, MI, USA); a protein kinase A (PKA) inhibitor, H-89 (1 μM, Sigma-Aldrich); a protein kinase B inhibitor, afuresertib (1 μM, ChemScene, Monmouth Junction, NJ, USA); a protein kinase C (PKC) inhibitor, Gö6983 (0.5 μM, Wako); a protein kinase D inhibitor, CID755673 (3 μM, Sigma-Aldrich); a calcium/calmodulin-dependent protein kinase II inhibitor, KN-93 (1 μM, Sigma-Aldrich); or an extracellular signal-regulated kinase inhibitor, SCH772984 (1 μM, AdooQ). However, pretreatment of an Src-family tyrosine kinase (SFK) and Abl tyrosine kinase inhibitor, bosutinib (2 μM, Sigma-Aldrich), or a CK2 inhibitor, quinalizarin (3 μM, Sigma-Aldrich), completely inhibited the effect of AngII.
We also found that overexpression of CSK, an endogenous inhibitor of SFKs (Okada, 2012) , inhibited AngII-induced activation of L-type Ca 2+ channels in HL-1 cardiomyocytes (Fig. 4B) .
CK2 is a heterotetramer consisting of two catalytic subunits (α and/or α') and two regulatory β subunits (Litchfield, 2003) . Knockdown of CK2α' or CK2β, but not CK2α, significantly suppressed the effect of AngII on L-type Ca 2+ channels in HL-1 cardiomyocytes (Fig. 4C) , indicating a requirement of CK2α'β in this response. Immunoblotting revealed that the expression level of CK2α' gradually decreased during maturation of the heart ( Fig. 5A and B) , and it was 7 and 4.5 times higher in Ordinate indicates the coupling efficiency (nA pC -1 ). Inset, voltage protocol. B-D, time-dependent effect of AngII (3 μM) on gating charge density (B), peak Ba 2+ tail current density (C) and the coupling efficiency (D) of L-type Ca 2+ channels in NVCMs (P0 or P1); n = 6-9 cells from 10-15 mouse pups in each time point.
* P < 0.05 versus each control (0 h). E, AngII did not alter the expression level of Ca V 1.2α 1c subunits in HL-1 cardiomyocytes. HL-1 cardiomyocytes were treated with AngII (3 μM) for the indicated duration. Whole-cell lysates (α 1c , 50 μg per lane; tubulin, 10 μg per lane) from these HL-1 cardiomyocytes were immunoblotted with antibodies against Ca V 1.2α 1c and tubulin. Tubulin was used as an internal control; n = 4 independent blots. * P < 0.05 versus control (0 h). In each panel contrast and brightness were adjusted to the whole image to make the features of interest clearer.
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NVCMs (P0) and HL-1 cardiomyocytes than in AVCMs (P56), respectively ( Fig. 5C and D) .
AngII sequentially activates SFKs and CK2α'β
The C-terminus of cardiac Ca V 1.2α 1c subunit is proteolytically processed in vivo (De Jongh et al. 1996) , and the cleaved distal C-terminus non-covalently rebinds through the distal C-terminus regulatory domain (DCRD) to their proximal C-terminal regulatory domain (PCRD), thereby autoinhibiting Ca V 1.2 channel activity (Fig. 6A ) (Gao et al. 2001; Hulme et al. 2006) . To determine the order in which SFKs and CK2 mediate the effect of AngII to Ca V 1.2 channels, we examined whether these kinases could directly reverse the autoinhibition of recombinant Ca V 1.2 channels. We cotransfected cDNA encoding c-Src or CK2 subunits with those encoding Ca V 1.2 1821, DCT, β 2C and α 2 δ 1 subunits in tsA201 cells. No increase in the coupling efficiency for Ca V 1.2 1821 + DCT channels was observed with coexpression of c-Src (Fig. 6A) . Overexpression of CK2α' , but not CK2α, CK2β or CK2αβ, slightly but significantly increased the coupling efficiency of Ca V 1.2 1821 + DCT channels (Fig. 6A) . Overexpression of CK2α'β significantly increased the coupling efficiency of Ca V 1.2 1821 + DCT channels to a level similar to that of Ca V 1.2 1821 channels (Fig. 6A) . Moreover, it did not further increase the coupling efficiency of Ca V 1.2 1821 channels. Threonine 1704 (Thr 1704 ) in the PCRD was reported to be the substrate of CK2 (Fuller et al. 2010) . Indeed, CK2α'β failed to activate Ca V 1.2 channels composed of Ca V 1.2 1821T1704A, DCT, β 2C and α 2 δ 1 subunits (Fig. 6B) , further suggesting that CK2α'β directly activates Ca V 1.2 channels.
To test how CK2α'β interacts with Ca V 1.2 channels, we coexpressed cDNA encoding HA-Ca V 1.2 [full-length (FL), 1821, or DCT], β 2C and α 2 δ 1 subunits with FLAG-CK2α' and FLAG-CK2β in tsA201 cells. FLAG-CK2α' and FLAG-CK2β both co-immunoprecipitated with HAFLCa V 1.2 and HA-Ca V 1.2 1821 channels but not HA-DCT (Fig 6C) . Furthermore, when either FLAG-CK2α' or FLAG-CK2β was individually coexpressed with HA-Ca V 1.2 1821, FLAG-CK2β but not FLAG-CK2α' co-immunoprecipitated with HA-Ca V 1. J Physiol 595.13 channels (Fig. 6D) . Thus, it is likely that CK2α'β binds to Ca V 1.2 channels devoid of DCT through CK2β.
SFKs removes the inhibition of CK2α'β through p27
Although the effect of CK2α'β on Ca V 1.2 channels was tightly regulated by AngII in cardiomyocytes (Fig. 4) , CK2α'β activated Ca V 1.2 channels constitutively in tsA201 cells (Fig. 6A) . Therefore, there may be a means of inhibiting CK2α'β in cardiomyocytes, and this inhibitor might be released by AngII. It was reported that a cyclin-dependent kinase (CDK) inhibitor, p27, inhibits CK2α' in cardiomyocytes (Hauck et al. 2008) . We found that knockdown of p27 indeed constitutively activated L-type Ca 2+ channels in HL-1 cardiomyocytes (Fig. 7A) . This activity was almost completely inhibited by A and B, mouse VCMs [embryonic days (E) 14.5 from 3 pregnant mice, E19.5 from 3 pregnant mice, P0 from 5 pups in each sample, P10 from 3 mice, P28 from 3 mice and P56 from 3 mice] were extracted. These whole-cell lysates (10 μg per lane) were immunoblotted with indicated antibodies. Data were normalized to each P0 group; n = 3 independent blots. * P < 0.05 versus each P0 group. C and D, expression levels of CK2α, α' and β in NVCMs (P0) and HL-1 cardiomyocytes and AVCMs (P56). Whole-cell lysates (10 μg per lane) were immunoblotted with indicated antibodies. Data were normalized to tubulin; n = 3 independent blots. † P < 0.05 versus each NVCM (P0) group, # P < 0.05 versus HL-1 cardiomyocytes group. Representative immunoblot (A and C) and summary of the data (B and D) are shown. In each panel contrast and brightness were adjusted to the whole image to make the features of interest clearer. Statistical significance was determined by ANOVA followed by Dunnett's test (B) and Bonferroni correction (D). (A and B) . C and D, CK2α'β bound to Ca V 1.2 1821 through CK2β subunits. HA-Ca V 1.2 channels, FLAG-CK2α' and FLAG-CK2β were expressed in tsA201 cells as indicated. Antibody-tagged protein complexes were co-immunoprecipitated (IP) with non-immune IgG or antibody against HA from lysates and analysed by immunoblotting (IB) with antibodies against HA and FLAG as indicated. Data are representative from three independent experiments. C, co-immunoprecipitation of HA-Ca V 1.2 (FL, 1821 or DCT) channels with FLAG-CK2α' + FLAG-CK2β. D, HA-Ca V 1.2 1821 channels and either FLAG-CK2α' (left) or FLAG-CK2β (right) were expressed in tsA201 cells. Co-immunoprecipitation of HA-Ca V 1.2 1821 channels with FLAG-CK2α' (left) or FLAG-CK2β (right). In each panel contrast and brightness were adjusted to the whole image to make the features of interest clearer. . AngII removes the inhibitory effect of p27 on CK2α'β through SFKs and activates Ca V 1.2 channels A, effect of sh-p27#2 on peak Ca V 1.2 channel current density at 0 mV in HL-1 cardiomyocytes in the presence of bosutinib (2 μM), quinalizarin (3 μM) or AngII (3 μM, 2 h). * P < 0.01 versus basal of mock. B and C, p27 bound to CK2α'β with (C) or without (B) Ca V 1.2 1821 channels in tsA201 cells. B, Myc-p27, FLAG-CK2α' and FLAG-CK2β were expressed in tsA201 cells. C, HA-Ca V 1.2 1821 channels, Myc-p27, FLAG-CK2α' and FLAG-CK2β were expressed in tsA201 cells. D, AngII (3 μM, 2 h) did not alter the expression level of p27; n = 3 independent blots. * P < 0.05 versus AngII 0 h group. E, time-dependent effect of AngII (3 μM) on Tyr 88 phosphorylation of p27 (p27-pY88) in HL-1 cardiomyocytes; n = 3 independent blots. * P < 0.01 versus AngII 0 min group. F, effect of bosutinib on AngII-(3 μM, 2 h) dependent Tyr 88 phosphorylation in HL-1 cardiomyocytes. HL-1 cardiomyocytes were treated with vehicle or AngII (3 μM) for 2 h in the presence or absence of bosutinib (2 μM) before extraction; n = 4 independent blots. * P < 0.01 versus control in the absence of bosutinib. G, coupling efficiency of Ca V 1.2 1821 + DCT channels in tsA201 cells overexpressing indicated proteins. * P < 0.01 versus Ca V 1.2 1821 + DCT with Myc. The number of observed cells is indicated in the graph (A and G). H and I, effect of p27Y88E on interaction between CK2α'β and p27 (H) and Ca V 1.2 1821 channels (I) in tsA201 cells. H, Myc-p27 (WT or Y88E), FLAG-CK2α' and FLAG-CK2β were expressed in tsA201 cells. I, HA-Ca V 1.2 1821 channels, Myc-p27 (WT or Y88E), FLAG-CK2α' and FLAG-CK2β were expressed in tsA201 cells. IB and IP were performed with indicated antibodies and data are representative of three independent blots (A-F, H and I). In each panel contrast and brightness were adjusted to the whole image to make the features of interest clearer. quinalizarin (3 μM) but not bosutinib (2 μM), consistent with direct activation of Ca V 1.2 channels by CK2α'β but not SFKs (Fig. 7A) . Knockdown of p27 occluded the effect of AngII on L-type Ca 2+ channel activity (Fig. 7A) . Furthermore, Myc-p27 co-immunoprecipitated with both FLAG-CK2α' and FLAG-CK2β in tsA201 cells (Fig. 7B) . When HA-Ca V 1.2 1821 was coexpressed with Myc-p27, FLAG-CK2α' and FLAG-CK2β, HA-Ca V 1.2 1821 channels co-immunoprecipitated with not only FLAG-CK2α'β but also Myc-p27 (Fig. 7C) . Thus, it is likely that Ca V 1.2 channels, CK2α'β and p27 form a macromolecular complex. AngII did not alter the expression level of p27 for 2 h in HL-1 cardiomyocytes (Fig. 7D) .
We hypothesized that it is SFKs that remove the inhibitory effect of p27 on CK2α'β. A major phosphorylation site of p27 by SFKs is tyrosine 88 (Tyr 88 ), which plays an important role in regulating inhibition of CDK by p27 (Jakel et al. 2012) . AngII significantly increased Tyr 88 phosphorylation of p27 in HL-1 cardiomyocytes in a time-dependent manner between 5 and 120 min (Fig. 7E) . Pretreatment of bosutinib (2 μM) almost completely inhibited Tyr 88 phosphorylation of p27 by AngII in HL-1 cardiomyocytes (Fig. 7F) . In tsA201 cells, CK2α'β-mediated increase in the activity of Ca V 1.2 channels was completely inhibited by coexpression of wild-type (WT) p27 or a phosphorylation-resistant mutant of p27Y88F (Fig. 7G) . In contrast, a phosphomimetic mutant p27Y88E was unable to inhibit CK2α'β (Fig. 7G) . Furthermore, coexpression of c-Src fully reversed the inhibitory effect of WT p27 but not p27Y88F on CK2α'β (Fig. 7G ).
As assessed with immunoprecipitation, p27Y88E could bind to CK2α'β as efficiently as WT p27 in the presence (Fig. 7H) or absence of Ca V 1.2 1821 channels (Fig. 7I) . These results suggested that AngII does not physically dissociate p27 from CK2α'β but impairs the ability of p27 to inhibit CK2α'β through Tyr 88 phosphorylation by SFKs, thus leading to activation of Ca V 1.2 channels.
Discussion
We found that AngII augmented twitch Ca 2+ transients by activating L-type Ca 2+ channels in immature but not mature cardiomyocytes (Fig. 8) . AngII caused this effect through AT 1 receptors and β-arrestin2. β-Arrestin2 activated SFKs, which removed the inhibitory effect of p27 on CK2α'β. Then, CK2α'β phosphorylated Thr 1704 in the PCRD of Ca V 1.2α 1c subunits and reversed the autoinhibition of Ca V 1.2 channels by the DCT (Gao et al. 2001; Hulme et al. 2006) , thereby activating Ca V 1.2 channels. It was likely that Ca V 1.2 channels, CK2α'β and p27 formed a macromolecular complex. These results suggest that AngII may exert a positive inotropic effect through this novel signalling pathway in immature cardiomyocytes although we cannot exclude the possibility that other changes in Ca 2+ signalling may also contribute to an increase in Ca 2+ transients in response to AngII.
It has been of debate whether AngII causes a positive inotropic effect on the heart (Lefroy et al. 1996; Watanabe & Endoh, 1998; Petroff et al. 2000; Palomeque et al. 2006; Rajagopal et al. 2006; Liang et al. 2010; Acharya et al. 2011) and/or activates L-type Ca 2+ channels (Allen et al. 1988; Ikenouchi et al. 1994; Petroff et al. 2000; Aiello & Cingolani, 2001; Bkaily et al. 2005; Gassanov et al. 2006) . This controversy might have arisen at least in part because of the different ages of animals used in experiments. We found that the expression level of CK2α' subunits age-dependently decreased in the postnatal period (Fig. 5) . The expression level of p27 in cardiomyocytes also increases with age (Torella al. 2004) . These facts may explain the age-dependent inotropic effect of AngII. In a study using sheep perinatal fetuses (Acharya et al. 2011) , administration of AngII significantly increased +dP/dt max of the left ventricle by ß66%, consistent with our present observation. Lefkowitz and his colleagues reported that AT 1 receptors have a positive inotropic effect in adult mouse cardiomyocytes through cooperative action of G q/11 /PKC and β-arrestin2 (Rajagopal et al. 2006) . Thus, the molecular mechanisms underlying inotropic effects of AngII on mature cardiomyocytes may be different from that on immature cardiomyocytes.
AngII increased L-type Ca 2+ channel activity in a concentration-dependent manner with an EC 50 of 360 nM, an ß100 times higher value than that for AngII-induced contraction of mouse abdominal aorta (4.6 nM) (Zhou et al. 2003) . However, when rat NVCMs in culture were incubated with prorenin and angiotensinogen, cell proliferation equivalent to that induced by 100 nM AngII was observed, although the concentration of AngII in the medium remained < 1 nM (Saris et al. 2002) . Thus, the local RAS exposes cardiomyocytes to higher concentrations of AngII than those in the plasma. Therefore, the signalling system identified in this study may be driven by the local RAS in the heart.
The effect of AngII on L-type Ca 2+ channels was attenuated by inhibition of SFKs or CK2 (Fig. 4) . Both SFKs and CK2 are included in the interactome of β-arrestins (Xiao et al. 2007 ). However, we considered that SFKs work upstream to CK2α'β in this signalling system from the following three pieces of evidence. First, in tsA201 cells, overexpression of CK2α'β but not c-Src significantly activated recombinant Ca V 1.2 channels (Fig. 6A) . Second, the effect of AngII was almost completely inhibited by the alanine substitution of Thr 1704 , a substrate of CK2 (Fuller et al. 2010) (Fig. 6B) . Finally, in HL-1 cardiomyocytes, enhancement of L-type Ca 2+ channel activity by knockdown of p27 was inhibited by quinalizarin but not bosutinib (Fig. 7A) . However, because SFKs are also reported to directly phosphorylate and augment L-type Ca 2+ channel activity in native cells such as neurons, smooth muscle cells and cardiomyocytes (Hu et al. 1998; Bence-Hanulec et al. 2000; Dubuis et al. 2006; Gui et al. 2006) , AngII might upregulate L-type Ca 2+ channels not only through CK2α'β but also through SFKs. Hauck et al. (2008) reported that AngII activated CK2α' and thereby phosphorylated Ser 83 and Thr 187 of p27 in rat neonatal cardiomyocytes. These phosphorylations then impaired the ability of p27 to inhibit CK2α' . This is collectively suggestive of the existence of a positive feedback loop between p27 and CK2α' that is regulated by CK2α' itself. However, they did not identify what activated CK2α' first. We propose that it is SFKs that first phosphorylate Tyr 88 of p27 and impair its ability to inhibit CK2α' . This would then be followed by positive feedback between p27 and CK2α' . Indeed, SFKs significantly phosphorylated Tyr 88 of p27 as early as 5 min after stimulation with AngII (Fig. 7E) . In addition, the phosphorylation-resistant p27 mutant (Y88F) inhibited the effect of constitutively active CK2α' on Ca V 1.2 channels, both in the presence and in the absence of c-Src (Fig. 7G) . It was likely that physical dissociation of p27 from CK2α' is not necessary for the disinhibition of CK2α' (Fig. 7H and I) . Hauck et al. (2008) found that p27 knock-out mice had significantly higher contractility of the left ventricle, especially in adulthood. We speculated that this was because CK2α' activated Ca V 1.2 channels more strongly in the knock-out compared with WT mice in adulthood when p27 expression level was high.
In the heart, the C-terminus of most Ca V 1.2α 1c subunits is truncated (Gao et al. 1997) and reassociated with the PCRD, and autoinhibits Ca V 1.2 channels (Gao et al. 2001; Hulme et al. 2006) . PKA is bound to Ca V 1.2α 1c subunits through A-kinase anchoring proteins (AKAPs) associated with the distal C-terminus of the Ca V 1.2α 1c subunit (Marshall et al. 2011) . It phosphorylates Ser 1700 in the PCRD, and thereby attenuates the autoinhibitory effect of the distal C-terminus and activates Ca V 1.2 channels (Fuller et al. 2010) . We found that CK2α' was bound to Ca V 1.2α 1c subunits devoid of DCT through CK2β (Fig. 6C  and D) , phosphorylated Thr 1704 (Fig. 6B) , and thereby activated Ca V 1.2 channels (Fig. 6A) . Thus, it can be posited that what CK2β is for CK2α' is analogous to what AKAPs are for PKA. Because both Ser 1700 and Thr 1704 are located in close proximity at the interface between the DCRD and the PCRD (Fuller et al. 2010) , CK2α' may activate Ca V 1.2 channels in a manner similar to PKA. Indeed, CK2α'β like PKA increased the coupling efficiency between the voltage-sensing domain and the activation gate of Ca V 1.2 channels (Fig. 2) (Fuller et al. 2010) .
β-Adrenergic stimulation increases cardiac L-type Ca 2+ channel currents by ß100 to 200% within several minutes (McDonald et al. 1994 ). This response is transient and desensitized quickly. AngII was as efficacious as catecholamines in activating L-type Ca 2+ channel currents (Fig. 1) , but its effect was slower and more sustaining (Fig. 2) . This may be because catecholamines activate PKA through G proteins whereas AngII activates CK2α' through β-arrestin2 (Ahn et al. 2004; Shenoy et al. 2006) . In the perinatal period of mammals, catecholamines secreted from the adrenal medulla and circulating and local AngII play a crucial role in pups' response to circulatory stresses (Heymann et al. 1981) . These two systems may be complementary in regulating cardiac function in this period by means of their different time course of actions. The action of AngII on cardiac L-type Ca 2+ channels continues as long as > 18 h and seems to be important for subacute maintenance of the circulatory system in the perinatal period. However, we do not know the exact molecular mechanisms underlying the slow response of L-type Ca 2+ channels to AngII. Because SFKs submaximally phosphorylated p27 at 5 min after AT 1 receptor stimulation (Fig. 7E) , the rate-limiting step in this signalling pathway may exist at the step of disinhibition of CK2 or phosphorylation of Ca V 1.2 by CK2. In this context, it is of note that CK2 usually requires negative charges near its target serine/threonine for effective phosphorylation (Litchfield, 2003) . Thus, a negative charge added by coincident phosphorylation of Ser 1700 by PKA could enable CK2α'β to phosphorylate Thr 1704 more promptly.
We found that a β-arrestin-biased AT 1 receptor agonist TRV027 was as effective as AngII in activating L-type Ca 2+ channels (Fig. 3C) . This agent activates β-arrestins but inhibits G q/11 proteins coupled to AT 1 receptors and thus has an ideal profile for therapeutics against heart failure (Violin et al. 2010) . However, this drug failed to meet either the primary or the secondary endpoints in the phase 2b BLAST-AHF trial that enrolled adult patients (Felker et al. 2015; Greenberg, 2016) . In this regard, TRV027 decreased mean atrial pressure and pulmonary capillary wedge pressure but only modestly increased cardiac output in a tachypacing-induced heart failure model of adult canines (Boerrigter et al. 2012) . We speculate that this was because of the age-dependent effect of AT 1 receptors on cardiac L-type Ca 2+ channels. Thus, if we can extrapolate the present observation to humans, we consider that TRV027 might be more suitable for paediatric than for adult heart failure. In the field of children's health care, the little progress that has been made over the past decades for treating adult heart failure has been sufficiently translated into treatments regarding paediatric heart failure (Hsu & Pearson, 2009 ). Thus, β-arrestin-biased AT 1 receptor agonists, which have not only a positive inotropic effect but an anti-apoptotic effect on cardiomyocytes, may be used as valuable therapeutics for paediatric heart failure in the future (Kim et al. 2012) .
